Loading...

Intrexon

DB:I5X
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
I5X
DB
$714M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Intrexon Corporation engage in the engineering and industrialization of biology in the United States. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Intrexon has significant price volatility in the past 3 months.
I5X Share Price and Events
7 Day Returns
-18.1%
DB:I5X
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-75.3%
DB:I5X
-9.2%
DE Biotechs
-6.7%
DE Market
I5X Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Intrexon (I5X) -18.1% -24.1% -49% -75.3% -85.8% -74.1%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • I5X underperformed the Biotechs industry which returned -9.2% over the past year.
  • I5X underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
I5X
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Intrexon undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Intrexon. This is due to cash flow or dividend data being unavailable. The share price is €3.71.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intrexon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intrexon's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:I5X PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.93
NasdaqGS:XON Share Price ** NasdaqGS (2019-04-18) in USD $4.11
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intrexon.

DB:I5X PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:XON Share Price ÷ EPS (both in USD)

= 4.11 ÷ -3.93

-1.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intrexon is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Intrexon is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Intrexon's expected growth come at a high price?
Raw Data
DB:I5X PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
59.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Intrexon, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intrexon's assets?
Raw Data
DB:I5X PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.27
NasdaqGS:XON Share Price * NasdaqGS (2019-04-18) in USD $4.11
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:I5X PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:XON Share Price ÷ Book Value per Share (both in USD)

= 4.11 ÷ 2.27

1.81x

* Primary Listing of Intrexon.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intrexon is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Intrexon's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intrexon has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Intrexon expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intrexon expected to grow at an attractive rate?
  • Unable to compare Intrexon's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Intrexon's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Intrexon's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:I5X Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:I5X Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 59.7%
DB:I5X Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 5.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:I5X Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:I5X Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 212 -89 -111 1
2020-12-31 156 -104 -159 2
2019-12-31 155 -111 -158 4
DB:I5X Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 161 -124 -509
2018-09-30 194 -121 -196
2018-06-30 208 -114 -179
2018-03-31 217 -109 -132
2017-12-31 231 -104 -117
2017-09-30 200 -94 -134
2017-06-30 203 -88 -123
2017-03-31 201 -77 -154
2016-12-31 191 -49 -187
2016-09-30 186 -19 -175
2016-06-30 191 49 -184
2016-03-31 183 45 -176

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intrexon is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Intrexon's revenue is expected to grow by 5.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:I5X Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Intrexon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I5X Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.60 -0.60 -0.60 1.00
2020-12-31 -1.08 -0.71 -1.46 2.00
2019-12-31 -1.17 -0.60 -1.60 4.00
DB:I5X Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.93
2018-09-30 -1.55
2018-06-30 -1.43
2018-03-31 -1.08
2017-12-31 -0.98
2017-09-30 -1.12
2017-06-30 -1.04
2017-03-31 -1.30
2016-12-31 -1.58
2016-09-30 -1.49
2016-06-30 -1.59
2016-03-31 -1.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intrexon will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Intrexon's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intrexon has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Intrexon performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intrexon's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intrexon does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intrexon's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intrexon's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intrexon's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intrexon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I5X Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 160.57 -509.34 137.81
2018-09-30 194.42 -196.14 147.80
2018-06-30 207.99 -178.50 148.36
2018-03-31 216.90 -131.78 152.51
2017-12-31 230.98 -117.02 147.68
2017-09-30 199.96 -133.89 148.03
2017-06-30 202.92 -123.18 142.57
2017-03-31 201.24 -153.58 134.25
2016-12-31 190.93 -186.61 138.01
2016-09-30 186.42 -175.19 137.43
2016-06-30 190.80 -184.42 125.00
2016-03-31 183.19 -176.02 118.33
2015-12-31 173.61 -84.49 106.73
2015-09-30 163.20 -32.95 91.67
2015-06-30 131.03 -47.46 84.77
2015-03-31 97.93 -58.84 76.23
2014-12-31 71.93 -81.82 62.52
2014-09-30 47.98 -112.86 53.40
2014-06-30 32.83 -51.81 45.96
2014-03-31 27.73 -10.54 38.71
2013-12-31 23.76 -57.37 33.25
2013-09-30 23.12 -81.81 25.78
2013-06-30 20.01 -116.09 23.79
2013-03-31 16.04 -127.21 22.32
2012-12-31 13.77 -103.87 23.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intrexon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intrexon has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intrexon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intrexon's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intrexon has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Intrexon's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intrexon's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intrexon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intrexon's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Intrexon's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intrexon Company Filings, last reported 3 months ago.

DB:I5X Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 378.72 212.26 222.84
2018-09-30 555.44 183.88 247.29
2018-06-30 567.14 8.34 81.13
2018-03-31 634.12 8.25 123.50
2017-12-31 546.55 8.27 79.67
2017-09-30 553.18 8.35 108.72
2017-06-30 571.55 8.40 157.16
2017-03-31 550.16 8.41 205.23
2016-12-31 569.25 8.77 237.21
2016-09-30 608.42 8.97 236.55
2016-06-30 628.18 8.48 270.75
2016-03-31 674.83 9.04 260.39
2015-12-31 704.89 9.09 238.31
2015-09-30 729.62 9.59 216.30
2015-06-30 486.93 10.34 166.33
2015-03-31 653.35 10.35 181.48
2014-12-31 409.29 12.64 115.96
2014-09-30 379.84 11.47 123.08
2014-06-30 388.37 2.00 175.55
2014-03-31 431.90 1.81 222.81
2013-12-31 381.34 1.69 177.49
2013-09-30 391.21 2.57 197.89
2013-06-30 206.33 2.35 129.92
2013-03-31 127.74 2.29 60.00
2012-12-31 85.11 0.09 10.66
  • Intrexon's level of debt (56%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.4% vs 56% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intrexon has sufficient cash runway for 1.3 years based on current free cash flow.
  • Intrexon has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 68.7% each year.
X
Financial health checks
We assess Intrexon's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intrexon has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Intrexon's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intrexon dividends. Estimated to be 0% next year.
If you bought €2,000 of Intrexon shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intrexon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intrexon's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:I5X Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:I5X Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intrexon has not reported any payouts.
  • Unable to verify if Intrexon's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intrexon's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intrexon has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intrexon's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Intrexon's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intrexon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intrexon has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Intrexon's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
RJ Kirk
COMPENSATION $1,907,879
AGE 65
TENURE AS CEO 10 years
CEO Bio

Mr. Randal J. Kirk, also known as RJ, J.D., has been the Chief Executive Officer of Intrexon Corporation since April 2009. Mr. Kirk served as President of Intrexon Corporation since April 2009. He served as Acting President of Human Therapeutics Division at Intrexon Corporation until June 2011. Mr. Kirk serves as a Senior Managing Director, Chief Executive Officer and Chairman of Third Security, LLC. He founded the firm in March 1999. Mr. Kirk has been a Manager at New River Management Company, LLC since 1996. He served as the President and Chief Executive Officer at New River Pharmaceuticals Inc. from October 2001 and April 2007. Mr. Kirk founded New River Pharmaceuticals Inc. in 1996. He began his professional career in the private practice of law. Mr. Kirk co-founded General Injectables & Vaccines, Inc. in 1984. He also co-founded King Pharmaceuticals, Inc. in 1993. He has been the Chairman of the Board at New River Pharmaceuticals Inc. since 1996 and a Director since August 1996. He has been the Chairman of Landmark Scientific, Inc. since 1996. Mr. Kirk serves as the Chairman of Biological & Popular Culture LLC since September 2002 and the Chairman of its predecessor from October 1999 to September 2002. He has been the Chairman of Intrexon Corporation since February 2008 and Cyntellect Inc. since September 2008. He is a member of the Board of Directors of the Edward Via College of Osteopathic Medicine since May 2015. He has been a Director of Michael W. Cook Asset Management, Inc. since January 2003. He has been a Director of Intrexon Corporation since 2008. He has been a Director at Harvest Pharmaceuticals Inc. since December 2002. He served as a Director at ZIOPHARM Oncology, Inc. from January 12, 2011 to October 5, 2018. He was an Independent Director of Halozyme Therapeutics, Inc. since May 2007 until March 2018. He has served on the Virginia Bioinformatics Institute Policy Advisory Board since March 2004. He served as the Chairman of Board for Clinical Data since December 16, 2004 and April 2011. Mr. Kirk served as the Chairman of the Board at GIV prior to the sale of that company in 1998. Mr. Kirk served as the Director of Clinical Data from September 2002 to April 2011. He served as a Director of Scios Inc. from February 2000 until his resignation on May 15, 2002 and Howe and Rusling, Inc. from December 2001 to 2006. He was on the Governor's Economic Development and Jobs Creation Commission from April 2010 to October 2012. He had been a Member to the Board of Visitors at University of Virginia and Affiliated Schools from July 20, 2009 to October 2012. He served as a member of the Board of Directors of the Virginia University Research Partnership from July 2007 to November 2010. Mr. Kirk served on the Board of Visitors of Radford University since July 2003 to June 2009 and was elected Rector of the Board from September 2006 to September 2008. He Kirk served as a Director of the Radford University Foundation, Inc. from September 1998 to May 2011. He was appointed to the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012. Mr. Kirk received a JD from the University of Virginia and a BA in Business from Radford University.

CEO Compensation
  • RJ's compensation has increased whilst company is loss making.
  • RJ's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Intrexon management team in years:

7.1
Average Tenure
56
Average Age
  • The average tenure for the Intrexon management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

RJ Kirk

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
10 yrs

Rick Sterling

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
54
TENURE
12.3 yrs

Don Lehr

TITLE
Chief Legal Officer & Corporate Secretary
COMPENSATION
$3M
AGE
43
TENURE
8.3 yrs

Bob Walsh

TITLE
Senior Vice President of Energy & Fine Chemicals Platforms
COMPENSATION
$3M
AGE
60
TENURE
5.9 yrs

Jeff Perez

TITLE
Senior Vice President of Intellectual Property Affairs
COMPENSATION
$3M
AGE
46
TENURE
4.7 yrs

Thomas Reed

TITLE
Founder & Chief Science Officer
COMPENSATION
$573K
AGE
52
TENURE
21.3 yrs

Tom Bostick

TITLE
Chief Operating Officer
AGE
61
TENURE
1.4 yrs

Steven Harasym

TITLE
Vice President of Investor Relations
TENURE
1.3 yrs

Darryl Webster

TITLE
Senior Vice President of Intellectual Property
AGE
58
TENURE
9.3 yrs

Helen Sabzevari

TITLE
President of Precigen
AGE
56
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Intrexon board of directors in years:

8.8
Average Tenure
63
Average Age
  • The tenure for the Intrexon board of directors is about average.
Board of Directors

Cesar Alvarez

TITLE
Independent Director
COMPENSATION
$256K
AGE
70
TENURE
11.2 yrs

RJ Kirk

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
11.2 yrs

Jeff Kindler

TITLE
Independent Director
COMPENSATION
$256K
AGE
62
TENURE
7.4 yrs

Jim Turley

TITLE
Independent Director
COMPENSATION
$251K
AGE
63
TENURE
5 yrs

Robert Shapiro

TITLE
Lead Independent Director
COMPENSATION
$251K
AGE
79

Steven Frank

TITLE
Independent Director
COMPENSATION
$241K
AGE
58
TENURE
11.2 yrs

Dean Mitchell

TITLE
Independent Director
COMPENSATION
$251K
AGE
62
TENURE
10.1 yrs

Fred Hassan

TITLE
Director
COMPENSATION
$241K
AGE
72
TENURE
2.8 yrs

Vinita Gupta

TITLE
Director
COMPENSATION
$713K
AGE
50
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • Intrexon insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Mar 19 Sell Thomas Reed Individual 04. Mar 19 05. Mar 19 -227,800 €4.12 €-844,651
03. Jan 19 Sell Thomas Reed Individual 31. Dec 18 31. Dec 18 -30,000 €5.55 €-166,532
06. Jul 18 Buy Third Security, LLC Company 03. Jul 18 03. Jul 18 6,357,517 €11.47 €72,913,002
06. Jul 18 Buy Randal Kirk Individual 03. Jul 18 03. Jul 18 1,121,914 €11.47 €12,866,992
X
Management checks
We assess Intrexon's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intrexon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Intrexon Corporation engage in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Details
Name: Intrexon Corporation
I5X
Exchange: DB
Founded: 1998
$634,817,573
160,720,471
Website: http://www.dna.com
Address: Intrexon Corporation
20374 Seneca Meadows Parkway,
Germantown,
Maryland, 20876,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS XON Common Stock Nasdaq Global Select US USD 08. Aug 2013
DB I5X Common Stock Deutsche Boerse AG DE EUR 08. Aug 2013
Number of employees
Current staff
Staff numbers
931
Intrexon employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.